PVR and neoplasm: TIGIT co-inhibitory molecule is highly expressed on NK cells, CD8+ T cells and Tregs within the TME [188,189,190,191], whereas CD155 is widely expressed on tumor cells [192,193] and activates TIGIT signaling to dampen NK/T cell activation and development of an effective anti-tumor response [194,195].